Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1997-04-14
1998-06-02
Peselev, Elli
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
514 54, C07H 300
Patent
active
057602131
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE ART
The present invention relates to an immunoactivating agent, and more particularly relates to an immunoactivating agent comprising a microbially produced polysaccharide.
BACKGROUND ART
Chemical therapy is exemplified as a method for cancer treatment, but the chemical therapeutical agents used therefor usually have high toxicity and tend to produce unfavorable side effects. Under these circumstances, attention is attracted to the idea of preventing and treating cancer as well as bacterial and viral infections by enhancing immunity possessed by the organism itself, and it is desired to provide a substance having an immunoactivating function.
A variety of polysaccharides have been utilized in the fields of medicines, foods and cosmetics. Natural polysaccharides may be roughly classified into the following three types: plant-derived polysaccharides, animal-derived polysaccharides and microorganism-derived polysaccharides. Among them, the polysaccharides derived from microorganisms (microbially produced polysaccharides) have come to be used popularly for convenience of production and supply.
.beta.-1,3 glucans such as lentinan and krestin have been known as polysaccharides utilized for immunoactivating agent (Japanese Patent Publication (KOKOKU)) Nos. 55-12886, 56-46481, etc.). These polysaccharides are obtained as products by basidiomycetes, so that as compared with the polysaccharides produced by microorganisms, their productivity is not sufficient high, with the yield being usually less than 10% based on the cells. As an instance of acidic heteropolysaccharides having an immunoactivating activity, there is known a polysaccharic substance A29-PS disclosed in Japanese Patent Publication (KOKOKU) No. 1-59283, but its effect is not satisfactory.
The present invention has been made in view of the above circumstances, and its object is to provide an immunoactivating agent comprising a polysaccharide produced by a microorganism. As a result of the present inventors' earnest studies, it has been found that the polysaccharides produced by the bacteria of the genus Klebsiella have excellent immunoactivating activity and can be obtained with higher productivity than the basidiomycetes-produced polysaccharides such as lentinan and krestin, and have reached the present invention.
DISCLOSURE OF THE INVENTION
Thus, the aspect of the present invention lies in an immunoactivating agent comprising a polysaccharide consisting essentially of four types of saccharides, viz. glucuronic acid, rhamnose, galactose and glucose, and having a molar ratio of glucuronic acid:rhamnose:galactose:glucose of 0 to 1.2:2.4 to 3.6:0.8 to 1.2:0.8 to 2.4.
Hereinbelow the present invention is described in detail.
In the polysaccharide used for the immunoactivating agent of the present invention, usually glucuronic acid, galactose and glucose are D-form and rhamnose is L-form. The polysaccharides used in the present invention preferably have the following characteristics besides the features mentioned above.
The preferable molar ratio of the constituting sugars is glucuronic acid:rhamnose:galactose:glucose=0.8 to 1.2:2.4 to 3.6:0.8 to 1.2:0.8 to 1.2.
The molecular weight of the polysaccharide as measured by gel filtration chromatography is in the range of approximately 1.times.10.sup.3 to 10.times.10.sup.6.
The bonding form of L-rhamnose is (1.fwdarw.2) bond and (1.fwdarw.bond). (The constituting ratios of the above bonding forms are (1.fwdarw.2):(1.fwdarw.bond)=1.3 to 3.0:1.)
The bonding form of D-glucuronic acid is (1.fwdarw.3) bond and (1.fwdarw.4) bond.
The bonding form of D-galactose is (1.fwdarw.3) bond.
The bonding form of D-glucose is (1.fwdarw.2) bond.
The bonding configuration of L-rhamnose, D-glucuronic acid and D-glucose is .alpha., and the bonding configuration of D-galactose is .beta.. ##STR1## (wherein Rha, Gal, Glc and GlcUA represent rhamnose residue, galactose residue, glucose residue and glucuronic acid residue, respectively, and the numerical figures indicate the position of the glycoside bond). where the
REFERENCES:
patent: 5476656 (1995-12-01), Kawaguchi et al.
Ooiso Yoichi
Oomori Hitoshi
Sugihara Ryosuke
Conlin David G.
Neuner George W.
Peselev Elli
Tayca Corporation
LandOfFree
Immunoactivating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoactivating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoactivating agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1461400